SCHEMBL7875449

SCHEMBL7875449

CCC(C)C1=CCNCC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.35
GABRR1 P24046 2/20 0.35
BLM P54132 2/20 0.35
RGS12 O14924 1/20 0.35
CYP3A4 P08684 1/20 0.35
GABRR2 P28476 1/20 0.35
MAPK1 P28482 1/20 0.35
GNAI1 P63096 1/20 0.35
PMP22 Q01453 1/20 0.35
SIGMAR1 Q99720 2/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13531056 1.00 TSHR (0.35) TSHRGABRR1BLMRGS12CYP3A4
SCHEMBL25742658 0.85 TSHR (0.33) TSHRGABRR1BLMRGS12CYP3A4
SCHEMBL20804042 0.82 HTR2A (0.31) HTR2CHTR2AHTR2B
SCHEMBL12454185 0.82 TSHR (0.36) TSHRGABRR1BLMRGS12CYP3A4
SCHEMBL21100747 0.79 GPR84 (0.35) TSHRGABRR1BLMRGS12CYP3A4
SCHEMBL84437 0.79
SCHEMBL27479656 0.78 TSHR (0.38) TSHRGABRR1BLMRGS12CYP3A4
SCHEMBL15321420 0.77 TSHR (0.44) TSHRGABRR1BLMRGS12CYP3A4
SCHEMBL6252483 0.75 TSHR (0.40) TSHRGABRR1BLMRGS12CYP3A4
SCHEMBL8458912 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190016717-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2019-01-17 US disclosed
WO-2010118207-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS SCHERING CORPORATION (US) 2010-10-14 WO disclosed
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds GILEAD SCIENCES, INC. 2008-03-27 US disclosed
US-20070027116-A1 Therapeutic phosphonate derivatives GILEAD SCIENCES, INC. 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027116-A1 Therapeutic phosphonate derivatives PPP5C, PPP3CA, PPP4R3A TSHR 3549/4885GABRR1 4219/4885BLM 4659/4885
US-20190016717-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS TBKBP1, TNKS1BP1, TNKS TSHR 2808/4885GABRR1 2658/4885BLM 1708/4885
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds TYMP, PNP, PIKFYVE TSHR 4778/4885GABRR1 2684/4885BLM 2478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.